Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LRAT | O95237 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28192562 | 1.00 | IGF2R (0.42) | IGF2RLMNAKDM4EALOX15LGALS8 | |
| SCHEMBL1450206 | 0.85 | GAA (0.51) | IGF2RKDM4ELGALS8RECQLGAA | |
| SCHEMBL20276334 | 0.85 | GAA (0.51) | IGF2RKDM4ELGALS8RECQLGAA | |
| SCHEMBL7122889 | 0.85 | GAA (0.51) | IGF2RKDM4ELGALS8RECQLGAA | |
| SCHEMBL20281053 | 0.85 | GAA (0.51) | IGF2RKDM4ELGALS8RECQLGAA | |
| SCHEMBL7122895 | 0.85 | GAA (0.51) | IGF2RKDM4ELGALS8RECQLGAA | |
| SCHEMBL20276318 | 0.85 | GAA (0.51) | IGF2RKDM4ELGALS8RECQLGAA | |
| SCHEMBL13811326 | 0.85 | GAA (0.51) | IGF2RKDM4ELGALS8RECQLGAA | |
| SCHEMBL1450204 | 0.85 | GAA (0.51) | IGF2RKDM4ELGALS8RECQLGAA | |
| SCHEMBL17274485 | 0.85 | GAA (0.51) | IGF2RKDM4ELGALS8RECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | IGF2R 1359/4885LMNA 1358/4885KDM4E 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.